About Vertex Pharmaceuticals
Vertex Pharmaceuticals benefits and support
Vertex Pharmaceuticals news and updates
Vertex Pharmaceuticals, Inc. invests into Genomics in $13.6M
In addition to the collaboration, Vertex also invested $13.6 million into a Series B financing round for Genomics plc.
Jan 1, 2018 | biospace.comVertex Pharmaceuticals, Inc. hires Semma
Semma will become a separate operating subsidiary of Vertex.
Jan 1, 2019 | biospace.comVertex Pharmaceuticals, Inc. hires Douglas Melton
In other news, Douglas Melton, one of the leading stem cell researchers in the world, is leaving Harvard University to join Vertex Pharmaceuticals to work on diabetes treatments.
Jan 1, 2022 | khn.orgVertex Pharmaceuticals, Inc. is developing version of VX-880
Vertex is also working on another version of VX-880 “encapsulated” in an immunoprotective device that’s surgically implanted.
Jan 1, 2022 | biopharmadive.comVertex Pharmaceuticals, Inc. is developing potential therapy for sickle cell disease and transfusion-dependent beta-thalassemia
The biotech is developing this potential therapy for sickle cell disease and transfusion-dependent beta-thalassemia in collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX).
Jan 1, 2022 | nasdaq.comVertex Pharmaceuticals, Inc. acquired Avatar Pharmaceutical Services on Jan 1st 10'.
Judy was the founder and president of Avatar Pharmaceutical Services which was acquired by Vertex Pharmaceuticals in 2010.
Jan 1, 2022 | worcester.eduVertex Pharmaceuticals, Inc. expanded facilities to New York, United States on May 17th 22'.
At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced plans to build another 344,000 square foot facility in the Seaport to support the company’s continued rapid growth, in particular the expansion of its cell and genetic therapies programs.
Jan 1, 2022 | businesswire.comCatalyst Biosciences, Inc sells assets to Vertex Pharmaceuticals, Inc. in the amount of $60M
Vertex Pharmaceuticals, a global biotechnology company, agreed to acquire the protease medicines portfolio from Catalyst Biosciences, a clinical-stage biopharmaceutical company, for $60m.
Jan 1, 2022 | mergerlinks.comVertex Pharmaceuticals, Inc. has issues with securities fraud or other unlawful business practices
The investigation concerns whether Vertex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Jan 1, 2022 | wbrc.comVertex Pharmaceuticals, Inc. launched clinical trial of VX-880, a stem cell-derived beta cell therapy in T1D on Jun 21st 22'.
Vertex launched its clinical trial of VX-880, a stem cell-derived beta cell therapy in T1D, in combination with immunosuppressive therapy to protect the cells from rejection, in the summer of 2021.
Jan 1, 2022 | jdrf.orgVertex Pharmaceuticals, Inc. acquired ViaCyte, Inc. for $320M on Jul 11th 22'.
Transaction Terms Under the terms of the acquisition, Vertex will acquire ViaCyte for $320 million in cash.
Jan 1, 2022 | biospace.comVertex Pharmaceuticals, Inc. partners with Year Up, Inc.
Vertex, a biotech pharmaceutical company, is addressing the talent gap within the biotech industry by partnering with Year Up, a Boston-based organization committed to closing the gap in opportunities for young adults in underserved communities.
Jan 1, 2022 | bizjournals.comVervetx partnered with Vertex Pharmaceuticals, Inc. on Jul 20th 22'.
On July 20, Verve Therapeutics, Inc., a biotechnology company pioneering a new approach to the care of cardiovascular disease, announced that it entered into an exclusive, four-year global research collaboration with Vertex Pharmaceuticals Incorporated, a global biotechnology company that invests in innovative and transformative medicines.
Jan 1, 2022 | wilmerhale.comVertex Pharmaceuticals, Inc. will develop gene-editing program on Jul 27th 22'.
On Wednesday, the company's announced a collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX ) to develop a gene-editing program to treat an undisclosed liver disease.
Jan 1, 2022 | marketwirenews.comVertex Pharmaceuticals, Inc. is developing DM1 drugs
Vertex, in turn, gets rights to develop DM1 drugs created through Entrada’s “EEV” technology platform — short for Endosomal Escape Vehicle.
Dec 8, 2022 | biopharmadive.comVertex Pharmaceuticals, Inc. is developing CFTR therapies with improved features
He said that Vertex Pharmaceuticals, the company that developed Trikafta, is also developing new CFTR therapies with improved features.
Dec 1, 2022 | wng.orgVertex Pharmaceuticals, Inc. partnered with Entrada Therapeutics, Inc. on Dec 8th 22'.
Vertex Pharmaceuticals has entered into an international partnership with Entrada Therapeutics to discover and develop intracellular Endosomal Escape Vehicle (EEV) therapeutics to treat myotonic dystrophy type 1 (DM1).
Dec 7, 2022 | pharmaceutical-technology.comVertex Pharmaceuticals, Inc. launches clinical trial to test VX-522
Vertex Pharmaceuticals is launching a clinical trial to test VX-522, its inhaled messenger RNA (mRNA) therapy for lung disease in cystic fibrosis (CF) patients who are not eligible for treatment with an existing CFTR modulator.
Dec 13, 2022 | cysticfibrosisnewstoday.comVertex Pharmaceuticals, Inc. hired Jonathan Biller as Chief Legal Officer on Sep 19th 22'.
Jonathan Biller has joined Vertex from Agios, where he held a variety of roles.
Sep 7, 2022 | law.com